Physician profile
Yaniv Fenig
NPI 1083029839
$662.22
in general payments reported to CMS, 2019-2025
12 companies · $218 in 2025
The $218 reported for 2025 was less than what a typical Transplant Surgery provider received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.77 · 2022: $153 · 2023: $125 · 2024: $151 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $494.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $146.31 | 2025 | Vistaseal, Ethicon, Evarrest |
| Sanofi-Aventis U.S. LLC | $125.01 | 2023 | |
| Veloxis Pharmaceuticals, INC. | $124.99 | 2022 | |
| Histosonics, INC. | $46.47 | 2024 | |
| Integra Lifesciences Corporation | $41.67 | 2024 | Cusa Clarity, Codman Hakim, Codman Certas |
| Olympus America INC. | $37.17 | 2025 | Olympus |
| Mallinckrodt Hospital Products INC. | $34.47 | 2025 | Terlivaz |
| Takeda Pharmaceuticals U.S.A., INC. | $28.44 | 2022 | |
| Merck Sharp & Dohme LLC | $24.02 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $20.70 | 2024 | Lokelma |
| Xvivo Perfusion INC. | $18.20 | 2024 | Xvivo Perfusion System (Xps) |
| Sirtex Medical INC | $14.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yaniv Fenig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.